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OBJECTIVE—Genome-wide association studies and linkage
studies have identiﬁed 20 validated genetic variants associated
with obesity and/or related phenotypes. The variants are com-
mon, and they individually exhibit small-to-modest effect sizes.
RESEARCH DESIGN AND METHODS—In this study we
investigate the combined effect of these variants and their ability
to discriminate between normal weight and overweight/obese
individuals. We applied receiver operating characteristics (ROC)
curves, and estimated the area under the ROC curve (AUC) as a
measure of the discriminatory ability. The analyses were per-
formed cross-sectionally in the population-based Inter99 cohort
where 1,725 normal weight, 1,519 overweight, and 681 obese
individuals were successfully genotyped for all 20 variants.
RESULTS—When combining all variants, the 10% of the study
participants who carried more than 22 risk-alleles showed a
signiﬁcant increase in probability of being both overweight with
an odds ratio of 2.00 (1.47–2.72), P  4.0  10
5, and obese with
an OR of 2.62 (1.76–3.92), P  6.4  10
7, compared with the 10%
of the study participants who carried less than 14 risk-alleles.
Discrimination ability for overweight and obesity, using the 20
single nucleotide polymorphisms (SNPs), was determined to
AUCs of 0.53 and 0.58, respectively. When combining SNP data
with conventional nongenetic risk factors of obesity, the discrim-
ination ability increased to 0.64 for overweight and 0.69 for
obesity. The latter is signiﬁcantly higher (P  0.001) than for the
nongenetic factors alone (AUC  0.67).
CONCLUSIONS—The discriminative value of the 20 validated
common obesity variants is at present time sparse and too weak
for clinical utility, however, they add to increase the discrimina-
tion ability of conventional nongenetic risk factors. Diabetes
59:1667–1673, 2010
T
he prevalence of obesity is increasing rapidly in
all parts of the world. The primary cause of the
current epidemic development is likely an un-
healthy lifestyle, especially high calorie intake
and insufﬁcient physical activity. However, studies have
established that the pathogenesis of obesity also includes
a genetic component predisposing some individuals to
gain more weight from a sedentary lifestyle (1–3). Until
2007 none of the suggested susceptibility variants for
common obesity were convincingly validated. Genome-
wide association studies (GWAS) have, however, with an
agnostic approach changed the success of identifying
common single nucleotide polymorphisms (SNPs), modi-
fying the risk for common complex diseases including
obesity. FTO was the ﬁrst well-replicated obesity suscep-
tibility locus to be identiﬁed through GWAS (4) and
moreover has been identiﬁed in other independent studies
(5–7).
Subsequently, variants downstream of MC4R (8,9) were
identiﬁed in meta-analyses of GWAS, and linkage peaks in
PCSK1 were re-sequenced identifying two coding variants
reaching the genome-wide signiﬁcance threshold (10). A
second wave of GWAS of obesity have recently identiﬁed
15 additional loci: TMEM18, SH2B1, KCTD15, NEGR1
(11,12), SEC16B, SFRS10, BDNF, FAIM2, BAT2 (11),
GNPDA2, MTCH2 (12), NCP1, MAF, PTER, and PRL (13).
Individually all of these common variants exert small-
to-modest effect sizes, however, whether the combined
effect of the 20 variants increases in an additive manner
has not been elucidated. So far the combined ability of
nine obesity variants to discriminate obese individuals
from lean individuals has been reported (14). In the
present study, we estimate the discriminative value of 20
SNPs in the 18 newly identiﬁed obesity loci in a Danish
population-based cohort both separately and in combina-
tion with conventional nongenetic risk factors of obesity.
We also examine whether the 20 obesity-related variants
exhibit additive combined effects or whether synergistic
effects caused by gene-gene interactions are present.
RESEARCH DESIGN AND METHODS
The 20 obesity susceptibility variants were genotyped in 6,514 individuals
from the Inter99 cohort, which is a population-based, randomized, nonphar-
macological intervention study of middle-aged Danes for the prevention of
ischemic heart disease conducted at the Research Centre for Prevention and
Health in Glostrup, Copenhagen (clinical trial registry no. NCT00289237) (15).
Body weight and height were measured in lightweight indoor clothes and
without shoes. BMI was deﬁned as weight in kilograms divided by height in
meters squared (kg/m
2). Overweight and obesity were deﬁned as 25 kg/m
2 
BMI 30 kg/m
2 and BMI 30 kg/m
2, respectively. A total of 6,510 individuals
had available information about BMI, and 2,831 were normal weight, 2,543
were overweight, and 1,136 were obese. All study participants were Danes by
self-report, and only individuals with Caucasian ethnicity were included in the
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Nongenetic risk factors in the population-based Inter99 cohort. All
participants completed a comprehensive questionnaire including questions
about education level, employment, dietary intake, medication, smoking
habits, and physical activity.
Educational level and employment were combined to a social status score
with ﬁve levels: 1) no education and unemployed, 2) 1 year of education or
more and unemployed, 3) no education and employed, 4) 1 to 3 years of
education and employed, and 5) four years or more of education and
employed. Smoking habits were divided into four classes: 1) never smoked, 2)
former smoker, 3) occasional smoker, and 4) daily smoker (16). A three-point
dietary score was developed based on a food frequency questionnaire (17) and
the method was validated in a thorough 28-day diet history and biomarker
analysis (n  264) (18). In short, the dietary score was based on questions
regarding the intake of fruits, raw and boiled vegetables, vegetarian dishes,
ﬁsh, and fat (both spread on bread and for preparation) to get a rough index
of the overall quality of dietary habits, which were divided into three
categories: 1) healthy, 2) moderate, and 3) unhealthy. In this study, informa-
tion about anti-obesity drugs was included as yes or no to the question, Do you
use anti-obesity drugs? Physical activity was assessed using a four level score
combining time spent when commuting and in leisure time, grouped into four
categories 1) 0–113 min/week, 2) 143–225 min/week, 3) 255–340 min/week,
and 4) 450–720 min/week (19).
Genotyping. The 10 variants in TMEM18, SH2B1, KCTD15, NEGR1, SEC16B,
SFRS10, BDNF, FAIM2, and BAT2 were genotyped using the Centaurus
platform (deCODE Genetics, Iceland) (11). The remaining 10 variants in FTO,
MC4R, PCSK1, GNPDA2, MTCH2, NCP1, MAF, PTER, and PRL were geno-
typed using Taqman allelic discrimination or KasPAR SNP Genotyping (KBio-
science, U.K.). When adjusting for the multiple tests performed, all SNPs
obeyed Hardy Weinberg equilibrium (P  0.05). All 20 SNPs passed quality
control with an average mismatch rate of 0.17% (max. 0.97%) and an average
success rate of 97.2% (min. 96.1%).
Statistical analyses. Logistic regression adjusted for sex and age was
applied to examine the effect of each variant on overweight and obesity.
Gene-gene interaction analyses were performed using logistic regression
comparing one model including only the main effect from each variant with an
alternative model including an interaction parameter besides the main effect.
Each SNP was included as a covariate coded as number of risk-alleles and the
pairwise interaction as the product of the pairs of SNPs, i.e., multiplicative
interaction.
The risk-alleles were deﬁned as alleles associated with increased risk of
overweight/obesity or BMI in previous studies (4–13). The effect of extreme
risk-proﬁles was evaluated using Fisher exact test, which assumes an equal
effect of all variants. Discriminatory value between normal weight, over-
weight, and obese individuals for the 20 variants and conventional nongenetic
risk factors separately and in combination was estimated using receiver
operating characteristic (ROC) curves. The models were trained on 1,000
bootstrap samples, with replacement, to cross-validate the results. A ROC
curve of disease status assessment was generated using the out-of-bag
samples by taking the mean of all bootstrap models in each 1-speciﬁcity point.
This enabled us to correct for the overﬁtting made by the apparent (or
optimal) ROC curve estimated in the entire dataset. ROC curve performance
was compared using the integrated discriminative improvement (IDI) score,
which will differ from zero if one ROC curve performs better. An asymptotic
test was used to test for signiﬁcance as described earlier (20). The ROC curves
were also evaluated using area under the curve (AUC) and Brier score. AUC
will be one if the test is perfect, and should be 0.80 to be of clinical value.
The Brier score will be zero if the test is perfect and will be 0.25 if the assigned
probability for an event (here normal weight or overweight/obese) based on
the parameters in the model is set to 50% (i.e., the test is useless), which
corresponds to an AUC of 0.5. The explained variance was estimated using the
generalized R
2 (21). All analyses were performed using RGui version 2.8.0
(http://www.r-project.org).
RESULTS
Of the 6,510 individuals with available BMI information,
genotyping data for all 20 variants was available for 3,925
individuals where 1,725 were normal weight, 1,519 were
overweight, and 681 were obese. Associations with over-
weight and obesity were analyzed individually for all
variants applying a multiplicative model introducing sex
and age as confounders (Fig. 1). Association with both
overweight and obesity was observed for FTO rs9939609,
MC4R rs12970134, BDNF rs4923461, and BDNF rs925946,
and the minor alleles were the risk-allele for all variants
except BDNF rs4923461. The minor allele of PCSK1 rs6232
associated with overweight but not obesity, whereas the
minor alleles of PCSK1 rs6235, SEC16B rs10913469,
FAIM2 rs7138803, GNPDA2 rs10938397, and MAF
rs1424233 and the major allele of TMEM18 rs7561317
associated with obesity but not overweight. No associa-
tions with either overweight or obesity were observed for
SH2B1 rs7498665, KCTD15 rs29941, NEGR1 rs2568958,
SFRS10 rs7647305, MTCH2 rs10838738, BAT2 rs2260000,
NCP1 rs1805081, PTER rs10508503, and PRL rs4712625 in
the present study of Danes (Fig. 1). Allelic OR (95% CI) for
the associated variants ranged from 1.12 (1.00–1.21)
(GNPDA2 rs10938397) to 1.25 (1.13–1.37) (BDNF rs4923461)
for overweight and from 1.12 (1.00–1.25) (PCSK1 rs6235)
to 1.44 (1.25–1.66) (TMEM18 rs7561317) for obesity. Some
of these individual variant analyses have been published
previously (22,23).
The combined effect of the 20 variants was estimated
calculating the percentage of normal weight individuals
and overweight/obese individuals stratiﬁed according to
the number of risk-alleles (Fig. 2A and B). The distribution
of risk-alleles followed a normal distribution in both case
and control subjects, but a shift toward higher number of
risk-alleles was observed among both overweight and
obese individuals.
Comparing a low risk proﬁle, deﬁned as the lowest 10th
percentile (14 risk-alleles), with a high risk proﬁle,
deﬁned as the highest 10th percentile (22 risk-alleles),
we found a considerably increased probability of being
both overweight, with an allelic OR of 2.00 (1.47–2.72), P 
4.0  10
5, and obese, with an allelic OR of 2.62 (1.76–
3.92), P  6.4  10
7.
We estimated the combined discriminatory ability of a
genetic test based on the 20 reported obesity susceptibility
variants by determining AUC and Brier scores of ROC
curves. AUC was estimated using cross-validation of 1,000
bootstrap samples. The discriminatory value of the 20
SNPs was higher for obesity than for overweight measured
by both AUC and Brier score (Table 1) consistent with the
fact that more SNPs associated with obesity than with
overweight (Fig. 1).
Discrimination ability of overweight and obesity using
only SNP data resulted in an AUC of 0.53 and 0.57,
respectively. When information regarding diet, physical
activity, smoking, education, employment, and use of
anti-obesity drugs was included together with sex and age
as nongenetic factors, discriminative value resulted in AUC
of 0.65 and 0.67 for overweight and obesity, respectively.
And when combining information regarding SNPs and
nongenetic risk factors, the AUC increased slightly for
obesity to 0.69, but decreased to 0.64 for overweight
(Table 1).
The slight increase in AUC gained when including SNP
information to conventional nongenetic risk factors of
obesity was estimated using IDI score, which will differ
from zero if one model assesses disease status better than
the other. The comparison resulted in an IDI score of 0.1
(P  0.001), and hence the additional discriminatory value
from SNPs is statistically signiﬁcant. The decrease in AUC
observed for overweight when including SNP data to
conventional obesity risk factors was likewise signiﬁcant
with an IDI score of 0.07 (P  0.001).
We observed no pairwise interactions among the SNPs ,
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testing (supplementary Fig. 1, available in an online ap-
pendix at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-1042/DC1).
The same phenomenon is illustrated by the fact that
models allowing for interactions among SNPs performed
worse than the original models assuming an additive effect
estimated by decreased AUC (supplementary Table 1).
The explained variance of obesity status increased from
11.9 to 16.8% in the analyzed study population by the
inclusion of SNP data to conventional risk factors,
whereas data of the 20 SNPs alone showed poor explana-
tion of obesity status with only 4.5% in the analyzed study
population (Table 1).
DISCUSSION
Four of 20 validated obesity/BMI SNPs associated with
both overweight and obesity, one variant associated with
overweight but not obesity, and six variants associated
with obesity but not overweight in the population-based
Inter99 cohort of middle-aged Danes. These different as-
sociation patterns could be due to modest gene-environ-
ment interactions, where the BMI level determines the
impact of the genetic variant. For example, that the BMI-
increasing effect of a variant emerges when the individual’s
BMI approaches 25 kg/m
2 and therefore only an association
with obesity is observed.
Combining all the variants and assuming an additive
effect, high risk proﬁle carriers had a 2.0- and 2.6-fold
increased probability of being overweight and obese,
respectively, compared with low risk proﬁle carriers.
Discrimination ability of overweight and obesity was not
sufﬁcient to be of clinical utility when using either SNPs or
conventional nongenetic risk factors of obesity. The ROC
AUC for obesity using SNP data separately was estimated
to 0.58 and to 0.67 for nongenetic risk factors. The
difference in the performance between two such tests can
be quantiﬁed by the false positive rate (1-speciﬁcity) for a
given true positive rate (sensitivity). As an example, if we
wanted to detect 80% of the obese individuals in the
population-based Inter99 cohort, this would result in a
misclassiﬁcation of 70% of the normal weight individuals
using only SNP information (Fig. 3A) whereas it would be
60% when using information about lifestyle (Fig. 3B).
Generally, the ability to discriminate between case and
control subjects was higher for obesity than for over-
weight. An explanation for the SNP data could be that
more variants associated with obesity than with over-
weight; an explanation for the nongenetic factors could be
that there is a better correlation between unhealthy life-
style and obesity, i.e., you are more likely to become obese
than overweight if you have an unhealthy lifestyle.
The highest ROC AUC of 0.69 was achieved when
combining SNPs and nongenetic factors. Despite the
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FIG. 1. Individual associations of BMI/obesity SNPs in the population-based Inter99 cohort comprising 2,831 normal weight, 2,543 overweight,
and 1,136 obese individuals.
Odds ratio (dots) and 95% CI (lines) for the 20 validated BMI/obesity SNPs individually, where overweight and obesity individuals were tested
against normal weight individuals, respectively, in the population-based Inter99 cohort. General linear models assuming an additive genetic
model and adjusting for sex and age were used. Black dots and lines indicate statistically signiﬁcant associations, whereas gray indicates
nonsigniﬁcant. The risk-alleles were deﬁned as the allele convincingly increasing the odds for overweight and/or obesity. For the 17 ﬁrst SNPs,
the deﬁned risk-allele was in accordance with previous studies (4–13), whereas for the last three SNPs (MAF rs1424233, PTER rs10508503, PRL
rs4712625) it was the opposite than in a previous study (13).
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information gained by adding SNPs to the nongenetic
factors was statistically signiﬁcant, estimated by the IDI
score. The false positive rate also decreased using this
model with 57% normal weight individuals being misclas-
siﬁed to detect 80% of the obese individuals (Fig. 3C). We
also observed a signiﬁcant decrease in the discriminative
ability between normal weight and overweight individuals
when adding SNP data to nongenetic data (AUC 0.65 vs.
0.64), which also could be explained by lower correlation
between SNPs and overweight.
A low discriminative ability between case and control
subjects for a common heterogeneous disease such as
obesity is in accordance with attempts to perform risk
assessment for other complex diseases. ROC analyses of
type 2 diabetes, also in the population-based Inter99
cohort, though including additional cases from other study
groups and using 19 validated type 2 diabetes variants,
also showed limited success with an ROC AUC of 0.60.
Sex, age, and BMI on the other hand was shown to be
strongly correlated with type 2 diabetes, hence, providing
a high discrimination ability with an AUC of 0.92, which
increased to 0.93 when including SNPs (24). We also
constructed ROC curves using only information regarding
sex and age. This resulted in an AUC of 0.61 and 0.64 for
overweight and obesity, respectively, changing to 0.62 and
0.63, respectively, when including SNP data (data not
shown). Hence, the effect of sex and age is stronger when
analyzing risk of type 2 diabetes compared with obesity,
where other lifestyle factors such as diet and physical
activity based on our analyses also play crucial roles.
Former attempts have been made to assess risk of obesity
using SNPs representing nine of the 18 BMI/obesity loci
included in this study (FTO, MC4R, TMEM18, GNPDA2,
SH2B1, KCTD15, MTCH2, NEGR1, and PCSK1). Here ROC
analyses resulted in an AUC of 0.58 when including all nine
SNPs in the model (14). This AUC represents the apparent
discriminatory power of the nine SNPs and is lower than
the apparent AUC observed in this study for the 20 gene
variants for obesity, which was 0.61 (data not shown).
Hence the 11 additional SNPs included in this study
contribute to an increase in the apparent discrimination
ability but in a magnitude that could indicate that the main
part of the discriminative ability is carried by the highly
obesity–associated SNPs in FTO and TMEM18 (Fig. 1).
ROC analyses assessing obesity—excluding the two vari-
ants in FTO and TMEM18—resulted in a mean AUC of 0.53
(data not shown), whereas analyses including only the two
variants in FTO and TMEM18 resulted in a mean AUC of
0.57. Both ﬁndings indicated that in our study sample, the
predominant contribution to the discriminative ability
comes from these two SNPs.
In the present study, we applied an additive model of
inheritance for all variants. In theory one could try to
examine the ﬁt of different models to the data to improve
discriminatory power; however, the ability to draw infer-
ences from a single study’s data are limited. Future
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FIG. 2. Studies of 1,725 normal weight, 1,519 overweight, and 681
obese individuals from the population-based Inter99 cohort stratiﬁed
according to number of validated BMI/obesity risk-alleles. The percent-
age of normal weight and overweight/obese individuals stratiﬁed ac-
cording to different risk-allele count in the population-based Inter99
cohort. The odds ratio comparing the lowest percentile (<14 risk-
alleles) with the highest percentile (>22 risk-alleles) was calculated
using Fisher exact test. Only individuals with successful genotyping for
all 20 variants were included.
TABLE 1
Measures of ROC curve and model performance on overweight and obesity in the population-based Inter99 using validated
BMI/obesity SNPs and nongenetic risk factors separately and in combination
Trait Included factors n AUC Brier score R
2
Overweight SNPs 3,244 0.53 0.25 0.019
Obesity SNPs 2,406 0.58* 0.20 0.045
Overweight Nongenetic 4,468 0.65 0.23 0.094
Obesity Nongenetic 3,278 0.67* 0.18 0.119
Overweight SNPs  nongenetic 2,679 0.64 0.23 0.106
Obesity SNPs  nongenetic 1,968 0.69* 0.17 0.168
To perform the ROC analysis, information regarding all 20 validated BMI/obesity variants must be available when SNPs are the included
factors. Information regarding all conventional obesity risk factors must be available when nongenetic factors are the included factors, and
information regarding all 20 variants plus all conventional obesity risk factors must be available when SNPs and nongenetic factors are the
included factors. This explains the decreasing number of included individuals with increased number of included factors. R
2, partial R
2 for
explained variance. *graphically illustrated in Figure 3.
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exploration of how the available data ﬁt different models
of inheritance and to test if such models would change the
present result.
This study is performed in a population-based cohort
and it is therefore possible to estimate the explained
variance, represented by partial R
2. The explained vari-
ance was, as the AUC, highest for obesity. The explained
variance in obesity status was for the 20 BMI/obesity
variants estimated to 4.5%, whereas nongenetic risk fac-
tors explained 11.9%. The highest explained variance was,
however, achieved when combining gene variants and
nongenetic risk factors where 16.8% of the variation in
obesity status was explained for the analyzed study pop-
ulation. This establishes that gene variants contain valu-
able predictive information especially in combination with
other obesity risk factors.
The fact that some genetic variants could enhance each
others effect synergistically, or contrarily mask each oth-
ers effects through gene-gene interactions, plays an impor-
tant role in the theoretical understanding of complex
heterogenic diseases such as obesity. We analyzed the
possible pairwise interaction between all combinations of
SNP pairs but failed to detect any that would be signiﬁcant
after correction for multiple testing (supplementary Fig.
1). The suggestion that the effect of the genetic variants on
obesity mainly can be explained by log-additive effects
among the 20 examined genetic variants is supported by
ROC curves based on logistic regression models including
two-way genetic interaction terms. Here the discriminative
value decreases for all models, both including SNP infor-
mation exclusively, as well as when combining SNPs and
lifestyle factors (supplementary Table 1). This analysis
only indicates that two-way gene-gene interactions do not
exist between the 20 genetic variants included in this
study; however, such interactions between gene variants
that so far have been missed in GWAS might still be
important in the etiology of obesity.
Even though the identiﬁcation of these 20 common
obesity SNPs in 18 different loci is an advance in the
understanding of the genetic predisposition to obesity,
their isolated information is still too limited to be of any
predictive and preventive value. But we have shown in this
study that these variants contribute signiﬁcantly to the
conventional nongenetic lifestyle risk factors of obesity.
The fact that common variants with low penetrance show
limited predictive value is in agreement with a study where
40 genotypes were simulated in 1 million individuals under
different scenarios. Here the variants should all be com-
mon and exert effect sizes with an OR of 1.50–2.00 to have
discriminative abilities of clinical value (25).
It has, moreover, been proposed that accumulation of
low-frequency variants with large effect sizes contribute to
the pathogenesis of common complex diseases (26).
Therefore future technologies resulting in the re-sequenc-
ing of large parts of the human genome may reveal more
rare variants, which in combination with the known com-
mon variants identiﬁed by GWAS, might improve the
discriminative value of genetics factors, increasing it to
levels that are useful in the identiﬁcation of individuals at
high risk of becoming obese.
Summarizing the number of risk-alleles of 20 validated
common obesity SNPs showed an increased prevalence of
both overweight and obesity in carriers of 22 or more
risk-alleles. The discriminative value of the 20 SNPs on
obesity is low compared with conventional risk factors but
contributes signiﬁcantly when combined with conven-
tional risk factors. No gene-gene interactions were shown
between the examined variants.
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FIG. 3. ROC curves of validated BMI/obesity variants, nongenetic factors, and the combination in discrimination between lean and obese
individuals. ROC curves for the discrimination between normal weight and obese individuals in the population-based Inter99 cohort. The gray
shadowed area represents ROC curves obtained through bootstrap cross-validation (1,000). The mean of the bootstrapped ROC curves is
represented by a solid line, whereas the dotted line is the apparent (or optimal) ROC curve estimated from the original data. In order to be
included in the analysis all variants should be successfully genotyped and information regarding all nongenetic factors should be available,
leaving 2,406 in the analyses of SNPs alone, 3,278 with nongenetic factors, and 1,968 with all SNPs and nongenetic factors.
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